Valneva Stock Attempts a Rebound After Losing 36% in Three Months

Current Stock Performance

Valneva's stock is trading at €2.696, significantly below all its moving averages: MM20 at €3.51, MM50 at €4.06, and MM200 at €3.88. This gap confirms the downward trend that has been ongoing for several weeks, with the stock having lost 36.65% over three months. The RSI, at 28, signals an oversold zone, which partly explains the rebound observed this morning. Additionally, the price is in the lower part of the Bollinger Bands, at only 29% of the range between the lower bound (€1.61) and the upper bound (€5.40), confirming the selling pressure accumulated in recent weeks. The technical support identified at €2.58 held during the last sessions, providing a floor from which the stock is attempting to stabilize. The major resistance lies at €4.93, a level far removed from the current price. Over a week, the variation remains almost neutral (-0.52%), while the annual performance shows a decline of 4.4%.

Upcoming Financial Milestones

The group's next financial appointment is scheduled for May 7 with the publication of the first quarter 2026 results, followed by the annual general meeting on June 1. These milestones will be crucial in assessing the company's commercial and financial trajectory, particularly regarding its main vaccine programs. The stock is characterized by a negative beta of -0.08, indicating an almost total decoupling from market trends. Monthly volatility remains high at 22.85%, reflecting the range of price movements on the stock. In the health sector, comparables show a slightly positive session: Sanofi is up 0.41% and UCB advances by 0.96%, although these changes are not sufficient to explain the day's movement on Valneva.